The Human Epilepsy Project (HEP) is a multi-institutional series of prospective, observational studies to identify factors that predict disease outcome, progression, and treatment response among participants with epilepsy.

• HEP, conducted between 2012 and 2020, included 488 participants aged 12 to 60 years old with new onset focal epilepsy recruited in Australia, Canada, and the United States. Participants were followed for 5 years and contributed clinical measures, blood samples, magnetic resonance imaging (MRI) data, electroencephalograms (EEG), and seizure diary data.
• HEP2, which completed recruitment, includes 205 participants aged 16 to 65 years old with medication-resistant focal epilepsy in the United States. The study assesses changes in health status, treatments, quality of life, and health care costs. Blood samples are collected at designated points throughout the course of follow-up (target duration of 2 years).
• HEP3 is an ongoing study to identify predictive factors for different treatment responses to seizure medications. Eligible participants are at least 13 years old with newly diagnosed idiopathic generalized epilepsy. Participants will contribute biomarkers over the course of a 2-year follow-up period.